Life sciences companies have come through the crisis relatively well so far – not least because of their importance in vaccine development. But the Corona crisis has also left its marks on them. Non-urgent treatments have been postponed, reducing the demand for medicines in certain therapeutic areas. The M&A market has come to a temporary halt and companies are experiencing the consequences of relying on global supply chains. The acceleration of many digitalization projects has increased the risk of hacker attacks.

Currently, many life sciences companies are focused on further stabilizing their operations and bringing them in line with the requirements of the new reality. This raises a number of questions:

How do the business and operating models of life sciences companies change in the context of digitalization? How should the transaction strategy of companies be adapted to the new reality? What are the tax implications of operational changes? What can you do to better protect yourself against cyberattacks? Our life sciences experts answer these and other questions and explain what life sciences companies should tackle now to be ready for the future.

Click here for the German version of the page.